120 related articles for article (PubMed ID: 12582227)
1. DRF 2655: a unique molecule that reduces body weight and ameliorates metabolic abnormalities.
Vikramadithyan RK; Hiriyan J; Suresh J; Gershome C; Babu RK; Misra P; Rajagopalan R; Chakrabarti R
Obes Res; 2003 Feb; 11(2):292-303. PubMed ID: 12582227
[TBL] [Abstract][Full Text] [Related]
2. Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity.
Vikramadithyan RK; Chakrabarti R; Misra P; Premkumar M; Kumar SK; Rao CS; Ghosh A; Reddy KN; Uma C; Rajagopalan R
Metabolism; 2000 Nov; 49(11):1417-23. PubMed ID: 11092504
[TBL] [Abstract][Full Text] [Related]
3. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
[TBL] [Abstract][Full Text] [Related]
4. Studies on the euglycemic and hypolipidemic potentials of the novel indole analogue of thiazolidinedione, DRF 2189.
Chakrabarti R; Vikramadithyan RK; Dileepkumar T; Kumar KB; Kumar MP; Misra P; Rao PB; Lohray VB; Lohray BB; Rajagopalan R
Arzneimittelforschung; 1999 Nov; 49(11):905-11. PubMed ID: 10604043
[TBL] [Abstract][Full Text] [Related]
5. MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities.
Doebber TW; Kelly LJ; Zhou G; Meurer R; Biswas C; Li Y; Wu MS; Ippolito MC; Chao YS; Wang PR; Wright SD; Moller DE; Berger JP
Biochem Biophys Res Commun; 2004 May; 318(2):323-8. PubMed ID: 15120604
[TBL] [Abstract][Full Text] [Related]
6. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models.
Chakrabarti R; Vikramadithyan RK; Misra P; Hiriyan J; Raichur S; Damarla RK; Gershome C; Suresh J; Rajagopalan R
Br J Pharmacol; 2003 Oct; 140(3):527-37. PubMed ID: 12970088
[TBL] [Abstract][Full Text] [Related]
7. Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma.
Chakrabarti R; Misra P; Vikramadithyan RK; Premkumar M; Hiriyan J; Datla SR; Damarla RK; Suresh J; Rajagopalan R
Eur J Pharmacol; 2004 May; 491(2-3):195-206. PubMed ID: 15140637
[TBL] [Abstract][Full Text] [Related]
8. A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice.
Kuwabara K; Murakami K; Todo M; Aoki T; Asaki T; Murai M; Yano J
J Pharmacol Exp Ther; 2004 Jun; 309(3):970-7. PubMed ID: 14982965
[TBL] [Abstract][Full Text] [Related]
9. A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis.
Guo Q; Sahoo SP; Wang PR; Milot DP; Ippolito MC; Wu MS; Baffic J; Biswas C; Hernandez M; Lam MH; Sharma N; Han W; Kelly LJ; MacNaul KL; Zhou G; Desai R; Heck JV; Doebber TW; Berger JP; Moller DE; Sparrow CP; Chao YS; Wright SD
Endocrinology; 2004 Apr; 145(4):1640-8. PubMed ID: 14701675
[TBL] [Abstract][Full Text] [Related]
10. C333H, a novel PPARalpha/gamma dual agonist, has beneficial effects on insulin resistance and lipid metabolism.
Xu C; Wang LL; Liu HY; Zhou XB; Cao YL; Li S
Acta Pharmacol Sin; 2006 Feb; 27(2):223-8. PubMed ID: 16412273
[TBL] [Abstract][Full Text] [Related]
11. Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor alpha agonist.
Chen X; Matthews J; Zhou L; Pelton P; Liang Y; Xu J; Yang M; Cryan E; Rybczynski P; Demarest K
Metabolism; 2008 Nov; 57(11):1516-25. PubMed ID: 18940388
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism.
Gilde AJ; van der Lee KA; Willemsen PH; Chinetti G; van der Leij FR; van der Vusse GJ; Staels B; van Bilsen M
Circ Res; 2003 Mar; 92(5):518-24. PubMed ID: 12600885
[TBL] [Abstract][Full Text] [Related]
13. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome.
Tanaka T; Yamamoto J; Iwasaki S; Asaba H; Hamura H; Ikeda Y; Watanabe M; Magoori K; Ioka RX; Tachibana K; Watanabe Y; Uchiyama Y; Sumi K; Iguchi H; Ito S; Doi T; Hamakubo T; Naito M; Auwerx J; Yanagisawa M; Kodama T; Sakai J
Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15924-9. PubMed ID: 14676330
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor alpha is involved in the regulation of lipid metabolism by ginseng.
Yoon M; Lee H; Jeong S; Kim JJ; Nicol CJ; Nam KW; Kim M; Cho BG; Oh GT
Br J Pharmacol; 2003 Apr; 138(7):1295-302. PubMed ID: 12711630
[TBL] [Abstract][Full Text] [Related]
15. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the actions of peroxisome proliferator-activated receptor alpha on obesity by estrogen.
Jeong S; Yoon M
Obesity (Silver Spring); 2007 Jun; 15(6):1430-40. PubMed ID: 17557980
[TBL] [Abstract][Full Text] [Related]
17. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
[TBL] [Abstract][Full Text] [Related]
18. Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice.
Carmona MC; Louche K; Nibbelink M; Prunet B; Bross A; Desbazeille M; Dacquet C; Renard P; Casteilla L; PĂ©nicaud L
Int J Obes (Lond); 2005 Jul; 29(7):864-71. PubMed ID: 15917863
[TBL] [Abstract][Full Text] [Related]
19. (+)-Z-Bisdehydrodoisynolic acid ameliorates obesity and the metabolic syndrome in female ZDF rats.
Banz WJ; Davis J; Steinle JJ; Adler S; Oitker J; Winters TA; Higginbotham DA; Hou Y; Henry N; Peterson R; Meyers CY
Obes Res; 2005 Nov; 13(11):1915-24. PubMed ID: 16339123
[TBL] [Abstract][Full Text] [Related]
20. Phenotype of peroxisome proliferator-activated receptor-alpha(PPARalpha)deficient mice on mixed background fed high fat diet.
Kim BH; Won YS; Kim EY; Yoon M; Nam KT; Oh GT; Kim DY
J Vet Sci; 2003 Dec; 4(3):239-44. PubMed ID: 14685029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]